Brief: Syros Pharmaceuticals Q3 EPS USD -0.16 Vs. IBES Estimate USD -0.72
31/10/2024 11:30
Oct 31 (Reuters) - Syros Pharmaceuticals Q3 operating expenses USD 26.182 million. * Q3 income from operations USD -26.182 million vs. IBES estimate USD -28.8 million * Q3 net income USD -6.396 million vs. IBES estimate USD -29.1 million
Recent news on Syros Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Syros falls after blood cancer drug fails in late-stage trial